Evidence map›Paper›PMID 31754232›Full record

ArticleScientific reports2019

Atomistic simulations shed new light on the activation mechanisms of RORγ and classify it as Type III nuclear hormone receptor regarding ligand-binding paths.

Suwipa Saen-Oon, Estrella Lozoya, Victor Segarra, Victor Guallar, Robert Soliva

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Selective inhibitors of the PSEN1-gamma-secretase complex.The Journal of biological chemistry · 2023
    Article
  3. Recent PELE Developments and Applications in Drug Discovery Campaigns.International journal of molecular sciences · 2022
    Review
  4. Review
  5. RORγ Structural Plasticity and Druggability.International journal of molecular sciences · 2020
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Suwipa Saen-OonNostrum Biodiscovery, Jordi Girona 29, Nexus II D128, 08034, Barcelona, Spain.ORCID http://orcid.org/0000-0002-4101-245X
Estrella LozoyaMolecular Informatics Department, Almirall S.A., Laureà Miró 408-410, 08980, St. Feliu de Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2422-2233
Victor SegarraMolecular Informatics Department, Almirall S.A., Laureà Miró 408-410, 08980, St. Feliu de Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0001-7826-977X
Victor GuallarBarcelona Supercomputing Center (BSC), Jordi Girona 29, 08034, Barcelona, Spain.ORCID http://orcid.org/0000-0002-4580-1114
Robert SolivaNostrum Biodiscovery, Jordi Girona 29, Nexus II D128, 08034, Barcelona, Spain. rsoliva@nostrumbiodiscovery.com.ORCID http://orcid.org/0000-0003-0628-4342

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular recognition of the RORγ nuclear hormone receptor (NHR) ligand-binding domain (LBD) has been extensively studied with numerous X-ray crystal structures. However, the picture afforded by these complexes is static and does not fully explain the functional behavior of the LBD. In particular, the apo structure of the LBD seems to be in a fully active state, with no obvious differences to the agonist-bound structure. Further, several atypical in vivo inverse agonists have surprisingly been found to co-crystallize with the LBD in agonist mode (with co-activator), leading to a disconnection between molecular recognition and functional activity. Moreover, the experimental structures give no clues on how RORγ LBD binders access the interior of the LBD. To address all these points, we probe here, with a variety of simulation techniques, the fine structural balance of the RORγ LBD in its apo vs. holo form, the differences in flexibility and stability of the LBD in complex with agonists vs. inverse agonists and how binders diffuse in and out of the LBD in unbiased simulations. Our data conclusively point to the stability afforded by the so-called "agonist lock" between H479 and Y502 and the precise location of Helix 12 (H12) for the competence of the LBD to bind co-activator proteins. We observe the "water trapping" mechanism suggested previously for the atypical inverse agonists and discover a different behavior for the latter when co-activator is present or absent, which might help explain their conflicting data. Additionally, we unveil the same entry/exit path for agonists and inverse agonist into and out of the LBD for RORγ, suggesting it belongs to the type III NHR sub-family.

Indexed as

Binding SitesHumansLigandsNuclear Receptor Subfamily 1, Group F, Member 3Protein BindingProtein ConformationReceptors, Cytoplasmic and NuclearLigandsNuclear Receptor Subfamily 1, Group F, Member 3Receptors, Cytoplasmic and Nuclear

Identifiers

PMID31754232
PMCPMC6872664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.